BioSpace

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

作者 BioSpace

1 分钟阅读
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察